Who are Trasylol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Cyklokapron, Amicar, Tranexamic Acid Injectable Product, Tranexamic Acid plus standard of care, Tenecteplase or Alteplase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aprotinin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Trasylol — Competitive Intelligence Brief

Trasylol (APROTININ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic Agent. Area: Hematology.

marketed Antifibrinolytic Agent Plasminogen Hematology Live · refreshed every 30 min

Target snapshot

Trasylol (APROTININ) — Bayer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trasylol TARGET	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid Injectable Product	Tranexamic Acid Injectable Product	The University of Texas Health Science Center at San Antonio	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tenecteplase or Alteplase	Tenecteplase or Alteplase	Insel Gruppe AG, University Hospital Bern	marketed	Tissue plasminogen activator (tPA); fibrinolytic agent	Plasminogen; fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic Agent class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trasylol — Competitive Intelligence Brief. https://druglandscape.com/ci/aprotinin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab